Get the Stockscreener App
348.77
1.24%
-4.39
After Hours:
349.62
0.85
+0.24%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $348.77, with a volume of 2.27M.
It is down -1.24% in the last 24 hours and down -10.15% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$353.16
Open:
$355.66
24h Volume:
2.27M
Relative Volume:
0.86
Market Cap:
$188.01B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.50
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
+0.28%
1M Performance:
-10.15%
6M Performance:
+27.76%
1Y Performance:
+14.06%
1-Day Range:
$347.80
$355.66
1-Week Range:
$345.80
$358.00
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
348.77 | 188.01B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
878.24 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Here's What You Need to Know about Amgen, Inc's AMG-145 - Yahoo
Amgen Inc. $AMGN Shares Bought by Wealthcare Advisory Partners LLC - MarketBeat
Nova R Wealth Inc. Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate - simplywall.st
Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients - TradingView
In diabetes patients, Repatha cut first major heart event risk 31% - Stock Titan
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here is what to know beyond why Amgen Inc. (AMGN) is a trending stock - MSN
Anti-Cancer MAbS Market Report 2026-2030 Featuring - GlobeNewswire
Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players - Yahoo Finance Singapore
Amgen stock consolidates as leaders tout AI in medicine discovery and delivery - Traders Union
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Global X Japan Co. Ltd. Has $6.80 Million Position in Amgen Inc. $AMGN - MarketBeat
Dakota Wealth Management Acquires 4,581 Shares of Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation As Shares Show Mixed Short And Long Term Returns - simplywall.st
Amgen stock moves lower after Rep Luz Rivas joins Amgen Foundation students - Traders Union
Vanguard Group reports zero Amgen (AMGN) holdings after internal realignment - Stock Titan
Amgen Inc. Stock: Steady Biotech Leader with Strong Dividend Yield and Institutional Backing for Nor - AD HOC NEWS
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts - GlobeNewswire Inc.
National Wealth Management Group LLC Makes New $1.53 Million Investment in Amgen Inc. $AMGN - MarketBeat
FY2027 EPS Estimates for Amgen Increased by Erste Group Bank - MarketBeat
Ferguson Wellman Capital Management Inc. Has $102.76 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Czech National Bank - MarketBeat
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - sg.finance.yahoo.com
Amgen Named One of the 2026 World’s Most Ethical Companies® by Ethisphere - Amgen
Amgen Named One of the World’s Most Ethical Companies® by Ethisphere - Amgen
Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy - TipRanks
Wells Fargo raises its price target on Amgen (AMGN) to $390 from $375 - MSN
Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375 - Insider Monkey
Pensionfund Sabic Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Assenagon Asset Management S.A. Sells 59,138 Shares of Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation After Recent Share Price Pullback And Mixed Short Term Returns - Yahoo Finance
SG Americas Securities LLC Acquires 113,909 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by E. Ohman J or Asset Management AB - MarketBeat
Clear Trail Advisors LLC Takes Position in Amgen Inc. $AMGN - MarketBeat
Avanza Fonder AB Increases Holdings in Amgen Inc. $AMGN - MarketBeat
Lilly, Amgen Seek Fast Win in Suit Over Clinics in Discount Plan - Bloomberg Law News
The Genetic Puzzle of Heart Disease: Inside Amgen’s Commitment to Lp(a) - amgen.com
Marshall Financial Group LLC Purchases New Position in Amgen Inc. $AMGN - MarketBeat
180 Wealth Advisors LLC Acquires 6,535 Shares of Amgen Inc. $AMGN - MarketBeat
AMGN Technical Analysis | Trend, Signals & Chart Patterns | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen Inc stock faces institutional selling pressure amid mixed 13F filings and dividend stability - AD HOC NEWS
Amgen Shares Sold by Sarasin & Partners LLP - National Today
Amgen Inc. stock faces pressure amid pipeline setbacks and market rotation in biotech sector - AD HOC NEWS
Wealth Enhancement Advisory Services LLC Trims Stake in Amgen Inc. $AMGN - MarketBeat
Nordea Investment Management AB Sells 273,268 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Sarasin & Partners LLP - MarketBeat
How Amgen Makes Money - Investopedia
Amgen Inc. (AMGN) collaborates on ending anti-OX40 clinical studies - MSN
Is trending stock Amgen Inc. (AMGN) a buy now? - MSN
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
2.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):